Jovanović D, Djukanović Lj, Susić D, Funduk G, Jovanović Z, Dragojlović Z, Bogdanović G, Starcević-Bozović Z
Institute of Urology and Nephrology, Clinical Centre of Serbia, Belgrade.
Srp Arh Celok Lek. 1996;124 Suppl 1:47-9.
The effects of captopril on morphologic changes and clinical course of adriamycin (ADR) nephropathy in spontaneously hypertensive rats (SHR) were examined. After ADR infections rats were divided into two groups: ADR-C group (n = 20) given captopril (60 mg/kg per day) and ADR group (n = 19) receiving no antihypertensive treatment. SHR were examined every 6 weeks. Captopril normalized systemic blood pressure, but failed to prevent proteinuria. It slowed down renal function deterioration in the early stage of ADR nephropathy (weeks 6 and 12), but at the end of the study both groups had the same degree of renal failure irrespectively of whether blood pressure was well controlled with captopril or hypertension persisted. Captopril slowed down mesangial expansion in the early stages of ADR nephropathy, but at the end of the study there was no statistically significant difference between these two groups. Treatment with captopril also reduced the development of glomerular sclerosis.
研究了卡托普利对自发性高血压大鼠(SHR)阿霉素(ADR)肾病形态学变化和临床病程的影响。ADR感染后,大鼠被分为两组:ADR-C组(n = 20)给予卡托普利(每天60 mg/kg),ADR组(n = 19)不接受抗高血压治疗。每6周对SHR进行检查。卡托普利使全身血压恢复正常,但未能预防蛋白尿。它减缓了ADR肾病早期(第6周和第12周)的肾功能恶化,但在研究结束时,无论卡托普利是否能良好控制血压或高血压持续存在,两组的肾衰竭程度相同。卡托普利减缓了ADR肾病早期的系膜扩张,但在研究结束时,两组之间无统计学显著差异。卡托普利治疗还减少了肾小球硬化的发生。